In conclusion, this study demonstrated that PD‐L1, PD‐L2, and EGFR expression changed in 30%–40% of recurrent tumors, suggesting that marker expression in naive tumor specimens may not accurately reflect their status at recurrence. This evidence concerns the gene PDCD1LG2 and neoplasm.